1 – 10 of 15
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Fibrinogen-like protein 2 in gastrointestinal stromal tumour
(
- Contribution to journal › Article
- 2020
-
Mark
Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors : An Analysis of a Randomized Clinical Trial after 10-Year Follow-up
(
- Contribution to journal › Article
- 2019
-
Mark
Mitotic Count and Estimation of the Risk of GIST Recurrence in Patients Treated with Preoperative Imatinib
(
- Contribution to journal › Debate/Note/Editorial
- 2018
-
Mark
Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
(
- Contribution to journal › Article
-
Mark
Tumor PIK3CA genotype and prognosis in early-stage breast cancer : A pooled analysis of individual patient data
(
- Contribution to journal › Article
- 2017
-
Mark
SLUG transcription factor : A pro-survival and prognostic factor in gastrointestinal stromal tumour
(
- Contribution to journal › Article
-
Mark
Effect of KIT and PDGFRA mutations on survival in patients with gastrointestinal stromal tumors treated with adjuvant imatinib : An exploratory analysis of a randomized clinical trial
(
- Contribution to journal › Article
- 2016
-
Mark
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
(
- Contribution to journal › Article
-
Mark
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
(
- Contribution to journal › Article
- 2015
-
Mark
Radiotherapy for GIST progressing during or after tyrosine kinase inhibitor therapy: A prospective study.
(
- Contribution to journal › Article